Free shipping on orders over $200·99%+ purity — verified by independent US labs·Refer a colleague, earn $50 in credits·Free shipping on orders over $200·99%+ purity — verified by independent US labs·Refer a colleague, earn $50 in credits·
Return to Directory

AOD-9604

Technical Monograph

AOD-9604 is a synthetic peptide fragment of the C-terminal region (residues 177-191) of human growth hormone (hGH). Equipped with a tyrosine substitution at the N-terminus to stabilize the molecule, it exclusively replicates the lipolytic properties of native hGH without conferring somatotropic or insulin-resistant side effects.

Mechanism of Action

AOD-9604 upregulates the expression of the strictly lipolytic β3-adrenergic receptors in adipose tissue. It intensely stimulates lipolysis and inhibits lipogenesis within adipocytes. It lacks the binding domains required for full GH receptors, producing no IGF-1 elevation.

Pharmacological Detail

Triggers downstream activation of hormone-sensitive lipase (HSL) primarily via targeted engagement with β3-adrenoreceptors.

Pharmacodynamics

Selectively acts upon adipose sites characterized by high beta-3 receptor density. Causes robust triglyceride hydrolysis.

Pharmacokinetics

Rapid plasma clearance with sustained metabolic transcription shifts persisting for 24-48 hours.

Preclinical Observations & In Vitro Data

Consistently demonstrated high-velocity weight loss in obese phenotype animal models without negative metabolic derangements.

Preclinical (Obese Zucker Rats): Over 50% increase in lipolytic activity compared to control. Demonstrated >20% total body fat loss over an 8-week continuous trial.

Observed Timeline of Action

TimeframePharmacological Effect
2-4 hoursMeasurable uptick in systemic free fatty acid (FFA) mobilization.
Day 14Initial observable reduction in specific adipocyte volume via histology.

Abstract Highlights

  • Demonstrates isolated lipolytic activity strictly devoid of generalized anabolic effects
  • Activates β3-adrenergic pathways directly within white adipose tissue
  • Does not alter systemic glucose metabolism or insulin sensitivity

References

Heffernan M, et al. (2001)."Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment."Int J Obesity.

Chemical Specifications

1815.1 g/mol
C78H123N23O23S2
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Material Handling & Stability

Laboratory StorageLyophilized powder: Store at -20°C.
Aqueous StabilityReconstituted: Extremely susceptible to degradation if agitated. Store securely at 2-8°C. Maximum recommended holding duration of 14 days.

Strict Notice

THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.